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OBJECTIVES This study sought to evaluate myocardial contraction fraction (MCF) as an index of
myocardial shortening by comparison to conventional shortening indices in patients with
hypertensive hypertrophy, athletes with physiologic hypertrophy and sedentary normal adult
subjects.
BACKGROUND A significant percentage of patients with hypertensive hypertrophy have “normal” or
“preserved” left ventricular (LV) systolic function by conventional echocardiographic mea-
sures whereas their systolic function is depressed when measured by the two-dimensional
echocardiographic mid-wall shortening fraction (MWSF). A three-dimensional echocardio-
graphic measure of myocardial shortening analogous to MWSF has been lacking. We
describe a volumetric measure of myocardial shortening, the MCF, as the ratio of stroke
volume (SV) to myocardial volume (MV), and hypothesize that it may be useful to compare
myocardial performance in patients with different degrees and types of hypertrophy.
METHODS We compared the MCF using freehand three-dimensional echocardiographic reconstruction
of the LV to conventional measures of LV function (ejection fraction [EF], endocardial
shortening fraction [SF] and MWSF) in subjects with pathologic hypertensive hypertrophy,
heart failure symptoms and preserved EF (n  17), athletes with physiologic hypertrophy (n
 41) and normal sedentary adults (n  80).
RESULTS The EF was in the normal range for all three groups. The MCF was lower in hypertensive
hypertrophy compared with normal subjects (0.33  0.05 vs. 0.44  0.07, p  0.01). It also
successfully differentiated physiologic hypertrophy from normal subjects (0.50 0.05 vs. 0.44
 0.07, p  0.01). The endocardial SF did not distinguish athletes from normal subjects and
the MWSF did not distinguish hypertensive from physiologic hypertrophy.
CONCLUSIONS The MCF, a volumetric measure of myocardial shortening, demonstrates that myocardial
shortening is decreased in hypertensive hypertrophy and increased in physiologic hypertro-
phy. The MCF may be useful in assessing differences in myocardial performance in patients
with similar degrees of hypertrophy. (J Am Coll Cardiol 2002;40:325–9) © 2002 by the
American College of Cardiology Foundation
Assessment of ventricular function in patients with concen-
tric hypertrophy may be problematic. Many patients with
hypertrophy and heart failure (HF) symptoms may have
“normal” or “preserved” left ventricular (LV) systolic func-
tion by conventional measures (1). Endocardial measures of
ventricular function (shortening fraction [SF] or ejection
fraction [EF]) may demonstrate normal or enhanced func-
tion (2,3) while experimental (4–8) and clinical studies
using a mid-wall measure of ventricular function (mid-wall
shortening fraction [MWSF]) have demonstrated depressed
myocardial performance (9 –13). Although three-
dimensional echocardiography yields highly accurate vol-
umes and EF (14–16), a three-dimensional measure of
myocardial shortening analogous to the two-dimensional
MWSF has not been described. To address this, we describe
a three-dimensional, volumetric measure of myocardial
shortening, the myocardial contraction fraction (MCF), and
compare it with two-dimensional echocardiographic mea-
sures of ventricular performance, the endocardial SF and the
MWSF, as well as the three-dimensional EF in normal
subjects, patients with hypertensive hypertrophy and HF
and subjects with physiologic hypertrophy.
Stroke volume (SV) is a measure of ventricular perfor-
mance integrating the influence of all factors affecting the
ventricle: preload, afterload, contractility and geometry.
When it is assessed relative to end-diastolic pressure, fiber
length or volume, or a related parameter, ventricular func-
tion is described (17). As a measure of myocardial shorten-
ing, SV is most appropriately assessed relative to the
myocardium, and specifically to myocardial volume (MV),
because it is the myocardium that shortens. Thus, the MCF,
defined as the ratio of SV to MV (MCF  SV/MV), is a
measure of ventricular function. In this ratio, SV is a
measure of the amount by which the myocardium contracts
(i.e., shortens) during systole relative to the total MV,
although the myocardium itself has not undergone a reduc-
tion in volume (18). During systole the myocardium short-
ens and thickens, reducing its contained volume by the
amount of the SV. Therefore, the SV is a measure of the
amount of shortening and thickening that has occurred, and
its ratio to MV is an index of the fractional shortening of the
myocardium in volumetric terms.
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Because this ratio is independent of ventricular geometry,
we hypothesize that it may be a useful measure of myocar-
dial performance analogous to the two-dimensional MWSF
and may be better able to delineate differences in ventricular
function in patients with different degrees and types of
hypertrophy than conventional measures. To test this hy-
pothesis, we compared the MCF obtained by freehand
three-dimensional echocardiographic reconstruction of the
LV with conventional two-dimensional echocardiographic
measures of LV function in: 1) subjects with hypertensive
hypertrophy, HF symptoms and preserved EF; 2) sedentary
normal young to elderly adult male and female subjects; and
3) athletes with physiologic hypertrophy.
METHODS
Study subjects. All subjects were examined according to
institutional review board-approved protocols and gave
informed consent. The two groups of subjects with hyper-
trophy were: 1) healthy young adult endurance athletes (n
41); and 2) patients with hypertension, left ventricular
hypertrophy, previous symptoms of HF and normal or
“preserved” EFs (n  18). Endurance athletes were re-
cruited from a pool of subjects undergoing self-directed
programs in physical training. The athletes had a high level
of physical condition (mean maximal oxygen consumption
[VO2max]  SD was 50.6  11.9 ml/kg/min) and no
history or clinical evidence of cardiac disease. The patients
with hypertensive hypertrophy HF were recruited from
patients being seen for clinical symptoms. The hypertensive
patients had increased LV wall thickness with preserved EF
and clinical evidence of HF, defined by a reduction in
functional capacity with either fatigue or shortness of breath
with exertion. All these patients met criteria for diastolic
HF as defined by the European Society of Cardiology (19).
The mean VO2max for these patients with hypertensive
hypertrophy was 19.3  3.5 ml/kg/min. The third group
included normal sedentary young to elderly adult male and
female subjects without evidence of cardiovascular disease
by history, physical examination or echocardiography (n 
80).
Echocardiography. A standard two-dimensional echocar-
diographic examination was performed on each subject
before the three-dimensional echo data acquisition. The
same echocardiograph was used for both examinations. The
ventricular minor axis dimension and posterior wall thick-
ness were measured on the parasternal long axis view at a
position 1 cm below the tips of the mitral leaflets on three
independent beats. The measurements were averaged and
used to calculate endocardial SF and MWSF. The modified
ellipsoid two-shell model taking into account relative epi-
cardial migration of the mid-wall circumferential fibers with
systole was used to determine h, the thickness of the inner
myocardial shell at end-systole (20). Endocardial SF was
calculated using the formula:
SF  (D  S)/D
Mid-wall shortening fraction was then calculated using the
formula:
MWSF  ([D  2h]  [S  2h])/(D  2h)
where D  end-diastolic chamber dimension, h  end-
diastolic posterior wall thickness/2, S  end-systolic cham-
ber dimension and h  calculated thickness of the inner
myocardial shell at end-systole.
The equipment and procedures of freehand three-
dimensional echocardiography have been previously de-
scribed in detail (21–24). Briefly, the equipment consists of
a conventional real-time echocardiograph, a three-
dimensional acoustic spatial locater, a personal computer
and custom software. Images acquired from the real-time
scanner are digitized and saved in the computer along with
their corresponding spatial coordinates. For quantitative
ventriculography a series of 11 short axis video loops of the
ventricle are acquired. These loops include end-diastole and
end-systole, and span the ventricle from the inferior surface
of the aortic valve to the epicardial apex about one centi-
meter apart. Off-line the endocardial and epicardial bound-
aries of the images are traced in systole and diastole. From
these traced boundaries, four ventricular surfaces—
endocardial and epicardial at end-diastole and end-systole—
are reconstructed and their volume and surface area com-
puted. One complete data set was acquired for each subject
and analyzed immediately after acquisition. These data
provide ventricular chamber volume, MV, SV and the ratios
derived from these, EF and MCF. The analysis of each
ventricular reconstruction was performed by a single, highly
skilled cardiac sonographer (L. E-K. C.) who was blinded
during the course of acquisition and analysis of the data to
the concept of the MCF and the project to validate it.
Statistics. The differences between the groups for each
parameter, EF, endocardial SF, MCF and MWSF, were
compared using analysis of variance with Dunnett’s test to
determine significant differences from normal. Results are
expressed as mean  SD. A p value  0.05 was considered
statistically significant. SAS for Windows (Version 8.0,
SAS Institute Inc., Cary, North Carolina) was used for all
analyses.
Abbreviations and Acronyms
EF  ejection fraction
HF  heart failure
LV  left ventricle/ventricular
MCF  myocardial contraction fraction
MRI  magnetic resonance imaging
MV  myocardial volume
MWSF  mid-wall shortening fraction
SF  shortening fraction
SV  stroke volume
VO2max  maximal oxygen consumption
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RESULTS
Table 1 presents the clinical characteristics of the study
subjects, and Table 2 presents the echocardiographic char-
acteristics of our two groups of hypertrophy subjects and the
normal subjects. The hypertensive adults were older, and a
greater percentage of the athletes were male. As expected,
the blood pressure, relative wall thickness and LV mass
index were higher in the adults with hypertensive hypertro-
phy.
The mean and SD of EF, MCF, endocardial SF and
MWSF for our two hypertrophy groups as well as for our
normal subjects are shown in Table 3. The MCF was higher
in athletes with physiologic hypertrophy than in normal
subjects and lower in subjects with hypertensive hypertrophy
than in normal subjects (p  0.01). The difference in
endocardial SF between the normal subjects and athletes
was not significant, whereas it was, as expected, significantly
higher in the patients with hypertensive hypertrophy (p 
0.01). The MWSF was not significantly different among the
three groups. The EF was normal in all three groups. The
differences in EF between the normal subjects, patients with
hypertensive hypertrophy and athletes, although not clini-
cally significant, were statistically significant (p  0.01).
DISCUSSION
The primary finding of this study is that the MCF, a
three-dimensional volumetric measure of myocardial short-
ening, most clearly distinguishes the three groups whereas
conventional shortening parameters—EF, endocardial SF
and MWSF—do not. The MCF is increased in subjects
with physiologic hypertrophy (endurance athletes), reflect-
ing a relatively greater increase in SV than MV, and the
MCF is decreased in hypertensive hypertrophy, reflecting
the converse. The endocardial SF is increased in concentric
hypertrophy, due to geometric changes in the ventricle, but
does not differentiate physiologic hypertrophy from seden-
tary normal subjects. The MWSF is not significantly
different among the three groups. The lack of statistically
significant difference may be due to either variability of the
two-dimensional measurement, small sample size, or the
superimposition of clinical HF in the group with hyperten-
sive hypertrophy. The MWSF did not distinguish between
hypertensive and physiologic hypertrophy. Thus, the MCF
measures myocardial shortening in a manner qualitatively
similar to the MWSF and appears to be more useful
comparing and differentiating physiologic hypertrophy from
hypertensive hypertrophy than conventional measures. Its
utility for more general application in other groups of
patients requires further study.
Influence of chamber volume. The MCF incorporates
only SV in the numerator and MV in the denominator, thus
removing the geometric influence of chamber volume and
wall thickness from the shortening expression. Each of the
conventional indices of ventricular function—EF, SF and
MWSF—incorporates the end-diastolic chamber dimen-
sion or volume in its calculation. In the case of the MWSF,
the dimensions used are the sum of the ventricular dimen-
sion plus one-half the wall dimension. As a consequence,
assessment of shortening by these parameters is fully or
partially influenced by volume. By eliminating chamber
volume from the shortening assessment, the MCF expresses
the shortening relationship only in terms of that which
shortens, the myocardium.
Myocardial shortening abnormality. A decrease in the
MCF indicates abnormal myocardial shortening induced
either by hypertrophy or by intrinsic myocardial disease that
reduces SV. Geometric changes in hypertensive hypertro-
phy have been shown to mask a generalized myocardial
shortening abnormality not apparent when endocardial
measures of chamber function are employed (25). The
MWSF studies have identified reduced function in some
but not all hypertrophied subjects (11). The MWSF repre-
sents the contraction of the middle, circumferential layer of
myocardial fibers at the base of the ventricle. It is not
representative of all myocardial contraction because there is
significant heterogeneity of myocardial fiber shortening not
only from epicardium to endocardium, but also from apex to
base. The MCF confirms the findings of studies using
spatially modulated magnetic resonance imaging (MRI)
that show a generalized myocardial shortening abnormality
with hypertrophy (26). The latter studies show depressed
Table 2. Echocardiographic Characteristics of Study Groups
Sedentary
Normals
(Mean  SD)
Adult
Athletes
(Mean  SD)
Hypertensive
Hypertrophy
(Mean  SD)
LVDd (cm) 4.8  0.6 5.0  0.5 5.0  0.7
LVDs (cm) 3.2  0.5 3.4  0.5 3.1  0.6
PWT (cm) 1.0  0.1 0.97  0.12 1.42  0.3
RWT 0.42  .07 0.39  0.05 0.58  0.15
3D EDV (ml) 91.6  20.9 144.3  26.2 130.7  40.9
3D ESV (ml) 38.8  9.9 65.1  12.7 62.2  22.4
3D SV (ml) 52.8  12.1 79.5  14.6 68.1  20.3
3D MV (ml) 120.8  28.5 159.9  23.1 208.1  64.1
3D LVMI (g/m2.4) 35.4  6.0 46.0  5.6 63.1  20.2
LVDd (LVDs)  left ventricular end-diastolic (end-systolic) endocardial dimension;
PWT  posterior wall thickness; RWT  two-dimensional echo relative wall
thickness  2 posterior wall thickness/LVDd; 3D EDV  three-dimensional echo
end-diastolic volume; 3D ESV  three-dimensional echo end-systolic volume; 3D
LVMI  three-dimensional echo left ventricular mass in grams indexed to height in
meters raised to the power 2.4; 3D MV  three-dimensional echo myocardial
volume; 3D SV  three-dimensional echo stroke volume.
Table 1. Clinical Characteristics of Study Groups
Sedentary
Normals
(n  80)
Adult
Athletes
(n  41)
Hypertensive
Hypertrophy
(n  18)
Age 47  21 31  4 59  12
Gender (male/female) 37/43 30/11 9/8
Systolic blood pressure
(mm Hg)
132  12 113  8 161  19
Diastolic blood pressure
(mm Hg)
78  8 73  8 93  16
Heart rate 66  10 61  10 69  7
Results expressed as mean  SD where applicable.
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longitudinal as well as circumferential myocardial shorten-
ing in hypertensive hypertrophy (27).
Distinguishing physiologic from pathologic hypertro-
phy. The differentiation of physiologic from pathologic
hypertrophy has important clinical implications (28) and is
particularly difficult when distinguishing athletes from sub-
jects with mild forms of hypertrophic cardiomyopathy
(29,30). Previously proposed criteria include resting and/or
post-exercise LV diastolic dysfunction (31), a ventricular
wall thickness 16 mm (32), and more recently, tissue
Doppler assessment of diastolic function (33) and metabolic
exercise stress testing (34,35). In our study, the MCF, along
with peak VO2, differentiated subjects with hypertensive
hypertrophy and HF from endurance athletes with hyper-
trophy. The athletes in the present study were endurance
athletes, and our experience with this group may not apply
to athletes who participate primarily in strength training.
Further study of the MCF in subjects with hypertrophic
cardiomyopathy is needed.
Advantages. The MCF has a clear, simple, easily under-
stood definition. As a dimensionless index, analogous to the
EF, it easily permits comparison of myocardial shortening
between subjects. As an additional attribute, it may be easily
calculated by any three-dimensional tomographic tech-
nique, including MRI, computed tomography and three-
dimensional echocardiography. However, the MCF re-
quires accurate measurement of SV and MV, and its use
may be restricted to three-dimensional techniques. Esti-
mates of SV and MV obtained by two-dimensional tech-
niques and Doppler echocardiography probably are neither
sufficiently accurate nor reproducible to be comparable to
three-dimensional results.
Three-dimensional tomographic reconstruction of the
ventricle, whether by echocardiography, MRI or computed
tomography, is the most accurate and reproducible method
for obtaining chamber and MV at the present time (16). We
believe this accuracy and reproducibility are essential for
calculation of a useful MCF. Three-dimensional echocar-
diography and MRI have been shown to yield equivalent
results that are superior to m-mode and two-dimensional
echocardiographic techniques (36–39). The superior accu-
racy of three-dimensional tomographic reconstruction is
based on several characteristics. First, three-dimensional
methods avoid use of geometric assumptions by measuring
an additional spatial dimension. Second, in freehand three-
dimensional echocardiography, visual guidance of image
plane location decreases errors of image plane position.
Third, three-dimensional methods decrease sampling errors
by increasing about fivefold the number of images used to
represent the ventricle (40).
Study limitations. The results of this study are limited to
the groups of subjects studied. This study does not encom-
pass the full range of ventricular diseases encountered
clinically. For example, the MCF may not accurately reflect
myocardial function where shortening (SV) is affected by
valve disease. In the presence of regional disease, such as
coronary artery disease, the MCF, as a global parameter,
will reflect net myocardial shortening.
Conclusions. The MCF is a useful measure for assessing
myocardial shortening because it is independent of chamber
size whereas conventional measures are not. As a volumetric
measure of myocardial shortening, it parallels the two-
dimensional MWSF, confirming that myocardial shorten-
ing is decreased in hypertensive hypertrophy and increased
in physiologic hypertrophy. The MCF may be useful in
assessing differences in myocardial function in patients with
similar degrees of hypertrophy.
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